Evaluation of Modified Chitosan Nanomicelles with Carboplatin for Effective Treatment Against Ovarian Cancer Cell Types in Murine Model.
7 affiliations
- 1Department of Polymer and Biomaterials Science, Faculty of Chemical Technology and Engineering, West Pomeranian University of Technology in Szczecin, Szczecin, Poland.
- 2Department of Physiology, Pomeranian Medical University in Szczecin, Szczecin, Poland.
- 3Department of Biology, Parasitology and Pharmaceutical Botany, Pomeranian Medical University in Szczecin, Szczecin, Poland.
- 4Department of Pharmacology, Pomeranian Medical University in Szczecin, Szczecin, Poland.
- 5Laboratory of Pharmacodynamics, Pomeranian Medical University in Szczecin, Szczecin, Poland.
- 6Department of Functional Anatomy, Pomeranian Medical University in Szczecin, Szczecin, Poland.
- 7Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University in Szczecin, Szczecin, Poland.
Abstract
Introduction
The clinical efficacy of platinum-based chemotherapy in ovarian cancer is limited by insufficient drug retention within the peritoneal cavity and associated systemic toxicity. This study aimed to develop hydrophobically modified chitosan nanomicelles as a carrier system for localized carboplatin delivery.Methods
Hydrophobically modified chitosan nanomicelles were prepared using an oil-in-watr emulsification technique and characterized in terms of their physicochemical properties, stability, encapsulation efficiency, and drug release behaviour. In vitro studies were performed to assess biocompatibility and cellular internalization in MUC1-expressing SK-OV-3 ovarian cancer cells. The preliminary in vivo antitumour response to the carboplatin-loaded nanomicelles was further evaluated in a subcutaneous murine ovarian cancer xenograft model.Results
The obtained nanomicelles exhibited a mean hydrodynamic diameter of approximately 200 nm and an encapsulation efficiency of 44%. No quantifiable carboplatin release was detected within 24 h under the tested conditions; however, the absence of a quantifiable signal cannot distinguish limited early release from release below the quantifiable range of the analytical method. The nanomicelles demonstrated preliminary in vitro cytocompatibility in SK-OV-3 cells, with mean cell viability remaining above 70% under the tested conditions, and intracellular localization of the nanomicelles in MUC1-expressing SK-OV-3 cells was observed by confocal microscopy. At the end-point evaluation, tumours were significantly smaller in the nanomicelle-treated group than in the free-carboplatin group (p = 0.03), whereas exploratory longitudinal analysis of tumour-growth AUC showed no significant between-group difference (p = 0.67).Conclusion
Hydrophobically modified chitosan nanomicelles represent a feasible carrier platform for localized carboplatin delivery and warrant further investigation for potential intraperitoneal application. The observed drug encapsulation, lack of quantifiable carboplatin release during the 24-h study period, preliminary in vitro cytocompatibility in SK-OV-3 cells, cellular internalization, and preliminary antitumour response provide proof-of-concept support for continued evaluation of this carrier system.
Related
- Microenvironmental-Regulated Chondroitin Sulfate Nanomicelles for Inhibition of Breast Cancer Drug Resistance and Metastasis
- The lipid nanomicelles incorporating peptide vaccine and SN38 prodrug potentiate neoadjuvant chemo-immunotherapy.
- Experimental and Computational Characterization of Human Serum Albumin Recognition by Ga(III)-NOTA Dendrimer Nanomicelles with Distinct PET Biodistribution Profiles
- A mild, effective, and green micro-dissolution treatment for wool fiber using choline-ascorbic acid NADES
- Fatigue Cracking Resistance of Crumb Rubber-Modified Asphalt: Mechanisms, Testing Methods, and Multiscale Performance Evaluation from Binder to Field
BibTeX
@article{piegat2026evaluation,
title = {{Evaluation of Modified Chitosan Nanomicelles with Carboplatin for Effective Treatment Against Ovarian Cancer Cell Types in Murine Model.}},
author = {Agnieszka Piegat and Katarzyna Piotrowska and Danuta Kosik-Bogacka and Joanna Łapczuk-Romanska and Radosław Birger and Nina Komaniecka and Marek Drozdzik and Agnieszka Kempinska-Podhorodecka and Aneta Cymbaluk-Ploska},
journal = {International journal of nanomedicine},
year = {2026},
month = oct,
doi = {10.2147/ijn.s634858},
url = {https://europepmc.org/article/MED/42892969},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Evaluation of Modified Chitosan Nanomicelles with Carboplatin for Effective Treatment Against Ovarian Cancer Cell Types in Murine Model.
AU - Agnieszka Piegat
AU - Katarzyna Piotrowska
AU - Danuta Kosik-Bogacka
AU - Joanna Łapczuk-Romanska
AU - Radosław Birger
AU - Nina Komaniecka
AU - Marek Drozdzik
AU - Agnieszka Kempinska-Podhorodecka
AU - Aneta Cymbaluk-Ploska
PY - 2026
DA - 2026/10/12
JO - International journal of nanomedicine
DO - 10.2147/ijn.s634858
UR - https://europepmc.org/article/MED/42892969
AB - Introduction The clinical efficacy of platinum-based chemotherapy in ovarian cancer is limited by insufficient drug retention within the peritoneal cavity and associated systemic toxicity. This study aimed to develop hydrophobically modified chitosan nanomicelles as a carrier system for localized carboplatin delivery.Methods Hydrophobically modified chitosan nanomicelles were prepared using an oil-in-watr emulsification technique and characterized in terms of their physicochemical properties, stability, encapsulation efficiency, and drug release behaviour. In vitro studies were performed to assess biocompatibility and cellular internalization in MUC1-expressing SK-OV-3 ovarian cancer cells. The preliminary in vivo antitumour response to the carboplatin-loaded nanomicelles was further evaluated in a subcutaneous murine ovarian cancer xenograft model.Results The obtained nanomicelles exhibited a mean hydrodynamic diameter of approximately 200 nm and an encapsulation efficiency of 44%. No quantifiable carboplatin release was detected within 24 h under the tested conditions; however, the absence of a quantifiable signal cannot distinguish limited early release from release below the quantifiable range of the analytical method. The nanomicelles demonstrated preliminary in vitro cytocompatibility in SK-OV-3 cells, with mean cell viability remaining above 70% under the tested conditions, and intracellular localization of the nanomicelles in MUC1-expressing SK-OV-3 cells was observed by confocal microscopy. At the end-point evaluation, tumours were significantly smaller in the nanomicelle-treated group than in the free-carboplatin group (p = 0.03), whereas exploratory longitudinal analysis of tumour-growth AUC showed no significant between-group difference (p = 0.67).Conclusion Hydrophobically modified chitosan nanomicelles represent a feasible carrier platform for localized carboplatin delivery and warrant further investigation for potential intraperitoneal application. The observed drug encapsulation, lack of quantifiable carboplatin release during the 24-h study period, preliminary in vitro cytocompatibility in SK-OV-3 cells, cellular internalization, and preliminary antitumour response provide proof-of-concept support for continued evaluation of this carrier system.
SN - 1176-9114
SN - 1178-2013
ER -